We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing has to measure up. The small plant acquired in its Crucell purchase just won't support its advancing pipeline candidates—and certainly not product launches down the road.